Covaxin Capable Of Dealing With New COVID Strains, Says Bharat Biotech Chairman

Hyderabad: COVID-19 vaccine, Covaxin will be effective in treating the new strain that has created a panic worldwide, Bharat Biotech said on Tuesday.

According to Bharat Biotech Chairman and Managing Director Krishna Ella, the protein components of inactive Covaxin can take care of mutations, reported news agency IANS.

Ella’s comments came amid increasing concerns over new strains of coronavirus SARS-CoV-2, especially the variant that was detected recently in the United Kingdom.

Ella, who was delivering the Telangana Academy of Sciences-organised ninth Dr Manohar VN Shirodkar Memorial Lecture, observed that any virus is likely to have a lot of mutation.

Covaxin is being developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

ALSO READ: Oxford Vaccine Will Protect 95 Per Cent: AstraZeneca CEO